Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extrachromosomal plasmid vectors for gene therapy.

Stephanie M Stoll1, Michele P Calos

  • 1Department of Genetics, Stanford University School of Medicine, CA 94305-5120, USA.

Current Opinion in Molecular Therapeutics
|September 12, 2002
PubMed
Summary

Extrachromosomal DNA, particularly plasmid DNA, offers significant advantages as a gene therapy vector over viral options. Its large capacity, stability, and reduced toxicity make it a promising tool for in vivo gene delivery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knock-in Blunt Ligation Utilizing CRISPR/Cas9.

Bio-protocol·2021
Same author

Nucleofection of phiC31 Integrase Protein Mediates Sequence-Specific Genomic Integration in Human Cells.

Journal of molecular biology·2020
Same author

Plasmid-Mediated Gene Therapy in Mouse Models of Limb Girdle Muscular Dystrophy.

Molecular therapy. Methods & clinical development·2020
Same author

Lack of RAC.

Molecular therapy : the journal of the American Society of Gene Therapy·2018
Same author

DNA-Mediated Gene Therapy in a Mouse Model of Limb Girdle Muscular Dystrophy 2B.

Molecular therapy. Methods & clinical development·2017
Same author

Use of the DICE (Dual Integrase Cassette Exchange) System.

Methods in molecular biology (Clifton, N.J.)·2017

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Gene Therapy

Background:

  • Extrachromosomal DNA is increasingly adopted for gene therapy applications.
  • Plasmid DNA presents distinct benefits compared to traditional viral vectors.
  • These benefits include enhanced packaging capacity, non-integrative stability, and lower toxicity profiles.

Purpose of the Study:

  • To review the advantages of using extrachromosomal DNA as a gene therapy vector.
  • To highlight recent advancements and successful applications of extrachromosomal DNA in vivo.

Main Methods:

  • Literature review of current research on extrachromosomal DNA in gene therapy.
  • Analysis of studies focusing on in vivo applications and delivery methods.
  • Synthesis of data on plasmid DNA advantages and successes.

Main Results:

  • Plasmid DNA demonstrates superior packaging capacity compared to viral vectors.
  • Non-integration into the host genome enhances plasmid DNA stability and safety.
  • Reduced toxicity is a key advantage of plasmid DNA gene therapy.
  • Various delivery techniques are being developed for effective tissue targeting.

Conclusions:

  • Extrachromosomal DNA, especially plasmid DNA, is a highly promising non-viral vector for gene therapy.
  • Its inherent advantages support its growing utilization in diverse in vivo therapeutic strategies.
  • Ongoing research and development continue to expand the potential of plasmid DNA for gene delivery.

Related Experiment Videos